Drug intelligence / Profile preview

Symtrex

Development stage: Unknown
Lead developer: Blue Heron Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Symtrex is a multivitamin and multimineral dietary supplement developed and marketed by Blue Heron Pharmaceuticals. Formulated as an oral tablet, it is designed to provide comprehensive nutritional support, particularly for individuals with increased requirements for iron and essential vitamins. The product typically contains a high dose of carbonyl iron (90 mg) and folic acid (1 mg), along with vitamins C, E, B6, B12, and minerals such as magnesium, zinc, and copper. Symtrex is used for the prevention and treatment of vitamin and mineral deficiencies, including iron-deficiency anemia, and is often marketed as a prescription-grade nutritional product.

Brand names: Symtrex
Other names: Symtrex Tablets

Beyond the preview

Go deeper on Symtrex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symtrex.

Explore the full profile